Novel potential avenues for the therapy of Tourette syndrome: Cannabinoid- and steroid-based interventions

No abstract is available for this paper.

• Publication year

  2022

• Venue

  International Review of Movement Disorders

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/bs.irmvd.2021.12.008
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Palmitoylethanolamide and hemp oil extract exert synergistic anti-nociceptive effects in mouse models of acute and chronic pain.

  2021cited by this paper
• Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray

  2021cited by this paper
• Allopregnanolone: The missing link to explain the effects of stress on tic exacerbation?

  2021cited by this paper
• Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study

  2021cited by this paper
• A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette's Syndrome.

  2021cited by this paper
• Palmitoylethanolamide: A Potential Alternative to Cannabidiol

  2021cited by this paper
• Allopregnanolone, the Neuromodulator Turned Therapeutic Agent: Thank You, Next?

  2020cited by this paper
• The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders

  2020cited by this paper
• Isoallopregnanolone reduces tic‐like behaviours in the D1CT‐7 mouse model of Tourette syndrome

  2020cited by this paper
• Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome

  2020cited by this paper
• Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey

  2019cited by this paper
• Single center experience with medical cannabis in Gilles de la Tourette syndrome.

  2019cited by this paper
• Cannabinoid Ligands Targeting TRP Channels

  2019cited by this paper
• Synthetic Cannabinoids-"Spice" Can Induce a Psychosis: A Brief Review.

  2019cited by this paper
• Altered Cortico–Striatal Functional Connectivity During Resting State in Obsessive–Compulsive Disorder

  2019cited by this paper
• Allopregnanolone is required for prepulse inhibition deficits induced by D1 dopamine receptor activation.

  2019cited by this paper
• Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience

  2019cited by this paper
• Acute Administration of URB597 Fatty Acid Amide Hydrolase Inhibitor Prevents Attentional Impairments by Distractors in Adolescent Mice

  2019cited by this paper
• Dopaminergic Disturbances in Tourette Syndrome: An Integrative Account.

  2018cited by this paper
• Role of the endocannabinoid system in drug addiction.

  2018cited by this paper
• Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report

  2018cited by this paper
• Tinkering with THC-to-CBD ratios in Marijuana

  2018cited by this paper
• P3-p15 Decreased Number of Parvalbumin and Cholinergic Interneurons in the Striatum of Individuals with Tourette Syndrome

  2018cited by this paper
• DARPP‐32 in the orchestration of responses to positive natural stimuli

  2018cited by this paper
• Prevalence of ADHD in Publicly Insured Adults

  2018cited by this paper
• Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474

  2017cited by this paper
• Modeling tics in rodents: Conceptual challenges and paths forward.

  2017cited by this paper
• Allopregnanolone mediates the exacerbation of Tourette-like responses by acute stress in mouse models

  2017cited by this paper
• Molecular Pharmacology of Phytocannabinoids.

  2017cited by this paper
• The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations

  2017cited by this paper
• Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial.

  2017cited by this paper
• Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome.

  2017cited by this paper
• Palmitoylethanolamide Modulates GPR55 Receptor Signaling in the Ventral Hippocampus to Regulate Mesolimbic Dopamine Activity, Social Interaction, and Memory Processing

  2017cited by this paper
• Tic Frequency Decreases during Short-term Psychosocial Stress – An Experimental Study on Children with Tic Disorders

  2016cited by this paper
• Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal

  2016cited by this paper
• The neurosteroidogenic enzyme 5α-reductase modulates the role of D1 dopamine receptors in rat sensorimotor gating.

  2016cited by this paper
• Testosterone and DHEA-S levels with chronic tic disorder in children

  2016cited by this paper
• The D1CT‐7 mouse model of Tourette syndrome displays sensorimotor gating deficits in response to spatial confinement

  2016cited by this paper
• Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy

  2016cited by this paper
• Endocannabinoid System: A Multi-Facet Therapeutic Target.

  2016cited by this paper
• Severe motor and vocal tics controlled with Sativex®

  2016cited by this paper
• Decreased Anterior Cingulate Cortex γ-Aminobutyric Acid in Youth With Tourette's Disorder.

  2016cited by this paper
• Palmitoylethanolamide Inhibits Glutamate Release in Rat Cerebrocortical Nerve Terminals

  2015cited by this paper
• Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know?

  2015cited by this paper
• Current pharmacotherapeutic approaches for the treatment of Tourette syndrome.

  2014cited by this paper
• Endocannabinoids Anandamide and 2-Arachidonoylglycerol Are Substrates for Human CYP2J2 Epoxygenase

  2014cited by this paper
• Interaction Between the Endocannabinoid and Serotonergic System in the Exhibition of Head Twitch Response in Four Mouse Strains

  2014cited by this paper
• Tic-related activity restriction as a predictor of emotional functioning and quality of life.

  2014cited by this paper
• Animal models of tic disorders: a translational perspective.

  2014cited by this paper
• Does Cannabidiol Protect Against Adverse Psychological Effects of THC?

  2013cited by this paper
• Interim Analysis of an Open-Label, Multi-Center Study of Ecopipam, a Dopamine D1 Receptor Antagonist, for Tic Reduction in Adults with Tourette Syndrome (P02.058)

  2013cited by this paper
• Inhibition of 5α-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice.

  2013cited by this paper
• The Implication of Neuroactive Steroids in Tourette's Syndrome Pathogenesis: A Role for 5α‐Reductase?

  2013cited by this paper
• Regional distribution of 5α-reductase type 2 in the adult rat brain: an immunohistochemical analysis.

  2013cited by this paper
• Functional imaging of dopaminergic neurotransmission in Tourette syndrome.

  2013cited by this paper
• Neuromodulation in Tourette syndrome: dopamine and beyond.

  2013cited by this paper
• Induction of the fatty acid 2-hydroxylase (FA2H) gene by Δ(9)-tetrahydrocannabinol in human breast cancer cells.

  2013cited by this paper
• A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

  2012cited by this paper
• Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

  2012cited by this paper
• Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome.

  2012cited by this paper
• Neurobiology of Tourette Syndrome: Current Status and Need for Further Investigation

  2011cited by this paper
• Neurosteroids and GABA-A Receptor Function

  2011cited by this paper
• The impact of a stress induction task on tic frequencies in youth with Tourette Syndrome.

  2011cited by this paper
• The major central endocannabinoid directly acts at GABAA receptors

  2011cited by this paper
• Prevalence and clinical correlates of tic disorders in a community sample of school-age children

  2011cited by this paper
• Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders.

  2011cited by this paper
• A preliminary study of finasteride in Tourette syndrome

  2011cited by this paper
• Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice.

  2011cited by this paper
• Neurosteroids: endogenous role in the human brain and therapeutic potentials.

  2010cited by this paper
• Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology

  2010cited by this paper
• Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis

  2010cited by this paper
• Neurobiological Substrates of Tourette's Disorder

  2010cited by this paper
• Cannabinoids for Tourette's Syndrome.

  2009cited by this paper
• Identification of intracellular carriers for the endocannabinoid anandamide

  2009cited by this paper
• Endocannabinoids and Nutrition

  2008cited by this paper
• Examining cortisol rhythmicity and responsivity to stress in children with Tourette syndrome.

  2008cited by this paper
• Antipsychotic-Like Properties of 5-α-Reductase Inhibitors

  2008cited by this paper
• Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates.

  2008cited by this paper
• GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current

  2008cited by this paper
• Treatment of Tourette's syndrome with finasteride.

  2007cited by this paper
• COX‐2 oxidative metabolite of endocannabinoid 2‐AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity

  2007cited by this paper
• Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress.

  2007cited by this paper
• The orphan receptor GPR55 is a novel cannabinoid receptor

  2007cited by this paper
• A new receptor for cannabinoid ligands

  2007cited by this paper
• Cannabinoid activation of PPARα; a novel neuroprotective mechanism

  2007cited by this paper
• A biosynthetic pathway for anandamide

  2006cited by this paper
• Preclinical models relevant to Tourette syndrome.

  2006cited by this paper
• Recent advances in Tourette syndrome research.

  2006cited by this paper
• BMC Clinical Pharmacology BioMed Central

  2006cited by this paper
• 3α-HYDROXY-5α-PREGNAN-20-ONE IN THE MIDBRAIN VENTRAL TEGMENTAL AREA MEDIATES SOCIAL, SEXUAL, AND AFFECTIVE BEHAVIORS

  2006cited by this paper
• The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide

  2005cited by this paper
• Correction for Gobbi et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis

  2005cited by this paper
• Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome.

  2005cited by this paper
• Epidemiological Survey of Tourette Syndrome in Children and Adolescents in Wenzhou of P.R. China

  2005cited by this paper
• Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones.

  2004cited by this paper
• Anandamide inhibits the DOI-induced head-twitch response in mice

  2004cited by this paper
• Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners*

  2004cited by this paper
• Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw

  2004cited by this paper
• [123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients.

  2004cited by this paper
• DARPP-32: an integrator of neurotransmission.

  2004cited by this paper

• No citing papers are available for this paper.